Answers are grounded in this paper and cite their sources.
Retrospective review evaluates dual mobility implant outcomes in high-risk patients, suggesting effective longevity and low dislocation rates.
Dual mobility (DM) is an established option in total hip arthroplasty (THA), though long-term data, particularly on whole construct outcomes remain very limited. We present a retrospective review of a consecutive series of high-risk patients selected using evidence-based criteria to undergo primary DM THA. Outcomes included re-operation for any cause, including peri-prosthetic fracture (PPF). Patients undergoing DM THA between March 2006 and October 2024 were identified using national digital health records capturing all healthcare episodes. The cohort comprised 318 cases with a mean age of 74.4 years (range 21.3–94.1). At a median follow-up of 7.4 years (range 1.0–19.6), Kaplan–Meier analysis demonstrated survivorship free from all-cause revision or major re-operation of 97.9% (95% CI 94.8–99.1). Non-osteoarthritis indications accounted for 39.6% of cases. There were 2 dislocations (0.63%) and 5 revisions (2 for prosthetic joint infection, 2 for PPF, and 1 for instability). Four additional PPFs were treated surgically (1 type B, 3 type C), and one was managed non-operatively. Post-operative PPF was the most common complication (2.2%), occurring at a mean of 3.5 years. Mean Oxford Hip Score improvement was 24.6. These findings support the long-term effectiveness of DM implants in patients at high risk of instability. PPF remains the leading cause of re-operation, likely reflecting a population also at high risk of falls. Careful consideration of patient and implant factors is essential when selecting bearing surfaces.
No takes yet. Share an insight, caveat, or question.
Hallikeri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: